Status:

COMPLETED

Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response

Lead Sponsor:

NYU Langone Health

Conditions:

Breast Cancer

Eligibility:

FEMALE

18+ years

Phase:

PHASE2

Brief Summary

The need to understand LABC is especially compelling in populations and countries with limited resources, where breast cancer incidence is relatively low, but mortality is comparably high. In these se...

Detailed Description

The term -locally advanced breast cancer (LABC) commonly includes tumors whose maximum diameter is 5 cm (T3) or larger, or which present with involvement of the chest wall or skin. Surprisingly, the s...

Eligibility Criteria

Inclusion

  • Biopsy proven locally-advanced breast cancer: IIB, IIIA, and IIIB
  • Metastatic breast cancer: limited to the subset of patients with intact breast, locally advanced tumor and involved ipsilateral supraclavicular nodes
  • Measureable disease required
  • Adequate laboratory values:
  • Hgb \> 10 ANC \> 1500 Platelets \> 150,000 Creatinine \< 1.5 Liver function \< 3x normal
  • Patient ≥ 18 years of age
  • Medically and psychologically able to comply with all study requirements
  • ECOG performance score 0-1
  • CT chest, abdomen, and pelvis performed
  • Mammogram or USG performed
  • Signed informed consent

Exclusion

  • Breast cancer patients with Stage 0, Stage I, or Stage IIA
  • Previous XRT or chemotherapy
  • Presence of distant metastases documented clinically or radiographically with the exception of ipsilateral supraclavicular nodes
  • Pregnancy
  • Inflammatory breast cancer
  • Patients under treatment (or who will have recently been treated) with anti-neoplastic, immunosuppressive or hormonal medications
  • Patients who are found to have a cancer positive for the marker HER-2/neu (applies only to NYU Tisch and Bellevue sites)

Key Trial Info

Start Date :

March 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 20 2018

Estimated Enrollment :

69 Patients enrolled

Trial Details

Trial ID

NCT02280252

Start Date

March 1 2005

End Date

December 20 2018

Last Update

November 23 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

NYU Langone Medical Center

New York, New York, United States, 10016